Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04516447 · ClinicalTrials.gov registry record · Phase 1

A Study of ZN-c3 in Patients With Ovarian Cancer

A Phase 1 study of Solid Tumor and Fallopian Tube Cancer, sponsored by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals.

Recruiting
Registry status
Phase 1
Development phase
140
Enrollment target
20
Study locations

NCT04516447 is a Phase 1 study of Solid Tumor and Fallopian Tube Cancer that is actively recruiting participants, run by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals. The registered enrollment target is 140 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (37% lower). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04516447, a Phase 1 study of Solid Tumor and Fallopian Tube Cancer, is actively recruiting participants, sponsored by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals.

RECRUITING
Registry status
Phase 1
Development phase
140 participants
Enrollment target
20
Study locations

Study Summary

This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability, preliminary clinical activity, pharmacokinetics (PK), and pharmacodynamics of ZN-c3 in combination with other drugs.

Conditions Studied

Solid Tumor Fallopian Tube Cancer Epithelial Ovarian Cancer Peritoneal Cancer

Interventions

  • DRUG Carboplatin
  • DRUG Paclitaxel
  • DRUG Gemcitabine
  • DRUG ZN-c3
  • DRUG Pegylated liposomal doxorubicin

Study Locations (20)

Other

  • Site 1001 - Banja Luka
  • Site 1002 - Sarajevo
  • Site 1003 - Tuzla
  • Site 1202 - Panagyurishte
  • Site 1201 - Sofia
  • Site 1401 - Tbilisi

Queensland

  • Site 2707 - South Brisbane
  • Site 2708 - Sunshine Coast

Victoria

  • Site 2716 - Melbourne
  • Site 2706 - Melbourne

Colorado

  • Site 0264 - Aurora

Massachusetts

  • Site 0104 - Boston

Missouri

  • Site 0111 - St Louis

New York

  • Site 0173 - New York

North Carolina

  • Site 0259 - Durham

Trial Details

FieldValue
Enrollment Target 140 participants
Start Date 2020-10-26
Est. Completion 2027-02-28
Phase Phase 1

Sponsor

K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals

8 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04516447

The ClinicalTrials.gov registry entry for NCT04516447 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (37% lower). The listed sponsor is K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, which has 8 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Solid Tumor appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.

NCT04516447 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Other, Queensland, Victoria.

Frequently Asked Questions

What is clinical trial NCT04516447 about?

NCT04516447 is a clinical study titled "A Study of ZN-c3 in Patients With Ovarian Cancer". This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability, preliminary clinical activity, pharmacokinetics (PK), and pharmacodynamics of ZN-c3 in combination with other drugs.

What is the current status of trial NCT04516447?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 140 participants. The study started on 2020-10-26. Estimated completion is 2027-02-28.

What conditions does trial NCT04516447 study?

This clinical trial studies the following conditions: Solid Tumor, Fallopian Tube Cancer, Epithelial Ovarian Cancer, Peritoneal Cancer.

What interventions are being tested in trial NCT04516447?

The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), Gemcitabine (DRUG), ZN-c3 (DRUG), Pegylated liposomal doxorubicin (DRUG).

Who is sponsoring clinical trial NCT04516447?

This trial is sponsored by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04516447 being conducted?

This trial has 20 study locations across Colorado, Massachusetts, Missouri, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Solid Tumor

All registered trials for this condition

Fallopian Tube Cancer

All registered trials for this condition

Colorado

All trials with a study site in Colorado

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.